1. Johns L. E., Houlston R. S. A systematic review and meta-analysis of familial colorectal cancer risk // Am J Gastroenterol. ‒ 2001. ‒ T. 96, № 10. ‒ C. 2992-3003.
2. Tenesa A., Dunlop M. G. New insights into the aetiology of colorectal cancer from genome-wide association studies // Nat Rev Genet. ‒ 2009. ‒ T. 10, № 6. ‒ C. 353-8.
3. Huxley R. R., Ansary-Moghaddam A., Clifton P., Czernichow S., Parr C. L., Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence // Int J Cancer. ‒ 2009. ‒ T. 125, № 1. ‒ C. 171-80.
4. Rasool S., Kadla S. A., Rasool V., Ganai B. A. A comparative overview of general risk factors associated with the incidence of colorectal cancer // Tumour Biol. ‒ 2013. ‒ T. 34, № 5. ‒ C. 2469-76.
5. Raskov H., Pommergaard H. C., Burcharth J., Rosenberg J. Colorectal carcinogenesis--update and perspectives // World J Gastroenterol. ‒ 2014. ‒ T. 20, № 48. ‒ C. 18151-64.
6. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой Злокачественные новообразования в России в 2021 году (заболеваемость и смертность) – М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, − 2022. − илл. − 252 с. //.
7. Board W. C. o. T. E. WHO classification of tumours // Book WHO classification of tumours / EditorWorld Health Organization Lyon, France, 2019.
8. Group M. S. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study // Radiology. ‒ 2007. ‒ T. 243, № 1. ‒ C. 132-9.
9. Glynne-Jones R., Wyrwicz L., Tiret E., Brown G., Rodel C., Cervantes A., Arnold D., Committee E. G. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann Oncol. ‒ 2018. ‒ T. 29, № Suppl 4. ‒ C. iv263.
10. Holland-Frei cancer medicine. / Bast Jr R. C., Croce C. M., Hait W. N., Hong W. K., Kufe D. W., Piccart-Gebhart M., Pollock R. E., Weichselbaum R. R., Wang H., Holland J. F.: John Wiley & Sons, 2017.
11. Steele S. R., Hull T. L., Read T. E., Saclarides T. J., Senagore A. J., Whitlow C. B. Correction to: The ASCRS Textbook of Colon and Rectal Surgery // The ASCRS Textbook of Colon and Rectal Surgery. ‒ 2016. ‒ C. E1-E1.
12. Malik S. S., Lythgoe M. P., McPhail M., Monahan K. J. Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis // Fam Cancer. ‒ 2018. ‒ T. 17, № 4. ‒ C. 557-564.
13. van Erp S. J., Leicher L. W., Hennink S. D., Ghorbanoghli Z., Breg S. A., Morreau H., Nielsen M., Hardwick J. C., Roukema J. A., Langers A. M. Identification of familial colorectal cancer and hereditary colorectal cancer syndromes through the Dutch population-screening program: results ofa pilot study // Scandinavian Journal of Gastroenterology. ‒ 2016. ‒ T. 51, № 10. ‒ C. 1227-1232.
14. Syngal S., Fox E. A., Eng C., Kolodner R. D., Garber J. E. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1 // J Med Genet. ‒ 2000. ‒ T. 37, № 9. ‒ C. 641-5.
15. Liu Z., Zhang Y., Niu Y., Li K., Liu X., Chen H., Gao C. A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer // PLoS One. ‒ 2014. ‒ T. 9, № 8. ‒ C. e103910.
16. Tanaka A., Sadahiro S., Suzuki T., Okada K., Saito G. Comparisons of Rigid Proctoscopy, Flexible Colonoscopy, and Digital Rectal Examination for Determining the Localization of Rectal Cancers // Dis Colon Rectum. ‒ 2018. ‒ T. 61, № 2. ‒ C. 202-206.
17. Chong A., Shah J. N., Levine M. S., Rubesin S. E., Laufer I., Ginsberg G. G., Long W. B., Kochman M. L. Diagnostic yield of barium enema examination after incomplete colonoscopy // Radiology. ‒ 2002. ‒ T. 223, № 3. ‒ C. 620-4.
18. Pickhardt P. J., Hassan C., Halligan S., Marmo R. Colorectal cancer: CT colonography and colonoscopy for detection--systematic review and meta-analysis // Radiology. ‒ 2011. ‒ T. 259, № 2. ‒ C. 393-405.
19. Kim J. H., Kim W. H., Kim T. I., Kim N. K., Lee K. Y., Kim M. J., Kim K. W. Incomplete colonoscopy in patients with occlusive colorectal cancer: usefulness of CT colonography according to tumor location // Yonsei Med J. ‒ 2007. ‒ T. 48, № 6. ‒ C. 934-41.
20. Neri E., Giusti P., Battolla L., Vagli P., Boraschi P., Lencioni R., Caramella D., Bartolozzi C. Colorectal cancer: role of CT colonography in preoperative evaluation after incomplete colonoscopy // Radiology. ‒ 2002. ‒ T. 223, № 3. ‒ C. 615-9.
21. Langevin J. M., Nivatvongs S. The true incidence of synchronous cancer of the large bowel. A prospective study // Am J Surg. ‒ 1984. ‒ T. 147, № 3. ‒ C. 330-3.
22. Mulder S. A., Kranse R., Damhuis R. A., de Wilt J. H., Ouwendijk R. J., Kuipers E. J., van Leerdam M. E. Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study // Cancer Epidemiol. ‒ 2011. ‒ T. 35, № 5. ‒ C. 442-7.
23. Martling A., Holm T., Bremmer S., Lindholm J., Cedermark B., Blomqvist L. Prognostic value of preoperative magnetic resonance imaging of the pelvis in rectal cancer // Br J Surg. ‒ 2003. ‒ T. 90, № 11. ‒ C. 1422-8.
24. Algebally A. M., Mohey N., Szmigielski W., Yousef R. R., Kohla S. The value of high-resolution MRI technique in patients with rectal carcinoma: pre-operative assessment of mesorectal fascia involvement, circumferential resection margin and local staging // Pol J Radiol. ‒ 2015. ‒ T. 80. ‒ C. 115-21.
25. Norenberg D., Sommer W. H., Thasler W., D'Haese J., Rentsch M., Kolben T., Schreyer A., Rist C., Reiser M., Armbruster M. Structured Reporting of Rectal Magnetic Resonance Imaging in Suspected Primary Rectal Cancer: Potential Benefits for Surgical Planning and Interdisciplinary Communication // Invest Radiol. ‒ 2017. ‒ T. 52, № 4. ‒ C. 232-239.
26. Battersby N. J., How P., Moran B., Stelzner S., West N. P., Branagan G., Strassburg J., Quirke P., Tekkis P., Pedersen B. G., Gudgeon M., Heald B., Brown G., Group M. I. S. Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study // Ann Surg. ‒ 2016. ‒ T. 263, № 4. ‒ C. 751-60.
27. Maas M., Beets-Tan R. G., Lambregts D. M., Lammering G., Nelemans P. J., Engelen S. M., van Dam R. M., Jansen R. L., Sosef M., Leijtens J. W., Hulsewe K. W., Buijsen J., Beets G. L. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer // J Clin Oncol. ‒ 2011. ‒ T. 29, № 35. ‒ C. 4633-40.
28. Fokas E., Appelt A., Glynne-Jones R., Beets G., Perez R., Garcia-Aguilar J., Rullier E., Smith J. J., Marijnen C., Peters F. P., van der Valk M., Beets-Tan R., Myint A. S., Gerard J. P., Bach S. P., Ghadimi M., Hofheinz R. D., Bujko K., Gani C., Haustermans K., Minsky B. D., Ludmir E., West N. P., Gambacorta M. A., Valentini V., Buyse M., Renehan A. G., Gilbert A., Sebag-Montefiore D., Rodel C. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer // Nat Rev Clin Oncol. ‒ 2021. ‒ T. 18, № 12. ‒ C. 805-816.
29. Sahni V. A., Silveira P. C., Sainani N. I., Khorasani R. Impact of a Structured Report Template on the Quality of MRI Reports for Rectal Cancer Staging // AJR Am J Roentgenol. ‒ 2015. ‒ T. 205, № 3. ‒ C. 584-8.
30. Vliegen R. F., Beets G. L., von Meyenfeldt M. F., Kessels A. G., Lemaire E. E., van Engelshoven J. M., Beets-Tan R. G. Rectal cancer: MR imaging in local staging--is gadolinium-based contrast material helpful? // Radiology. ‒ 2005. ‒ T. 234, № 1. ‒ C. 179-88.
31. Floriani I., Torri V., Rulli E., Garavaglia D., Compagnoni A., Salvolini L., Giovagnoni A. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis // J Magn Reson Imaging. ‒ 2010. ‒ T. 31, № 1. ‒ C. 19-31.
32. Schmoll H. J., Van Cutsem E., Stein A., Valentini V., Glimelius B., Haustermans K., Nordlinger B., van de Velde C. J., Balmana J., Regula J., Nagtegaal I. D., Beets-Tan R. G., Arnold D., Ciardiello F., Hoff P., Kerr D., Kohne C. H., Labianca R., Price T., Scheithauer W., Sobrero A., Tabernero J., Aderka D., Barroso S., Bodoky G., Douillard J. Y., El Ghazaly H., Gallardo J., Garin A., Glynne-Jones R., Jordan K., Meshcheryakov A., Papamichail D., Pfeiffer P., Souglakos I., Turhal S., Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making // Ann Oncol. ‒ 2012. ‒ T. 23, № 10. ‒ C. 2479-2516.
33. Niekel M. C., Bipat S., Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment // Radiology. ‒ 2010. ‒ T. 257, № 3. ‒ C. 674-84.
34. Choi S. H., Kim S. Y., Park S. H., Kim K. W., Lee J. Y., Lee S. S., Lee M. G. Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis: Systematic review and meta-analysis // J Magn Reson Imaging. ‒ 2018. ‒ T. 47, № 5. ‒ C. 1237-1250.
35. Ko Y., Kim J., Park J. K., Kim H., Cho J. Y., Kang S. B., Ahn S., Lee K. J., Lee K. H. Limited detection of small (</= 10 mm) colorectal liver metastasis at preoperative CT in patients undergoing liver resection // PLoS One. ‒ 2017. ‒ T. 12, № 12. ‒ C. e0189797.
36. Zech C. J., Korpraphong P., Huppertz A., Denecke T., Kim M. J., Tanomkiat W., Jonas E., Ba-Ssalamah A., group V. s. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases // Br J Surg. ‒ 2014. ‒ T. 101, № 6. ‒ C. 613-21.
37. Herrmann J., Lerman A., Sandhu N. P., Villarraga H. R., Mulvagh S. L., Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology // Mayo Clin Proc. ‒ 2014. ‒ T. 89, № 9. ‒ C. 1287-306.
38. Starck M., Bohe M., Simanaitis M., Valentin L. Rectal endosonography can distinguish benign rectal lesions from invasive early rectal cancers // Colorectal Dis. ‒ 2003. ‒ T. 5, № 3. ‒ C. 246-50.
39. Santoro G. A., Gizzi G., Pellegrini L., Battistella G., Di Falco G. The value of high-resolution three-dimensional endorectal ultrasonography in the management of submucosal invasive rectal tumors // Dis Colon Rectum. ‒ 2009. ‒ T. 52, № 11. ‒ C. 1837-43.
40. Zorcolo L., Fantola G., Cabras F., Marongiu L., D'Alia G., Casula G. Preoperative staging of patients with rectal tumors suitable for transanal endoscopic microsurgery (TEM): comparison of endorectal ultrasound and histopathologic findings // Surg Endosc. ‒ 2009. ‒ T. 23, № 6. ‒ C. 1384-9.
41. Roth E. S., Fetzer D. T., Barron B. J., Joseph U. A., Gayed I. W., Wan D. Q. Does colon cancer ever metastasize to bone first? a temporal analysis of colorectal cancer progression // BMC Cancer. ‒ 2009. ‒ T. 9. ‒ C. 274.
42. Augestad K. M., Bakaki P. M., Rose J., Crawshaw B. P., Lindsetmo R. O., Dorum L. M., Koroukian S. M., Delaney C. P. Metastatic spread pattern after curative colorectal cancer surgery. A retrospective, longitudinal analysis // Cancer Epidemiol. ‒ 2015. ‒ T. 39, № 5. ‒ C. 734-44.
43. Daza J. F., Solis N. M., Parpia S., Gallinger S., Moulton C. A., Belley-Cote E. P., Levine M. N., Serrano P. E. A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastases // Eur J Surg Oncol. ‒ 2019. ‒ T. 45, № 8. ‒ C. 1341-1348.
44. Muntean V., Oniu T., Lungoci C., Fabian O., Munteanu D., Molnar G., Bintintan V. Staging laparoscopy in digestive cancers // J Gastrointestin Liver Dis. ‒ 2009. ‒ T. 18, № 4. ‒ C. 461-7.
45. De Marco M. F., Janssen-Heijnen M. L., van der Heijden L. H., Coebergh J. W. Comorbidity and colorectal cancer according to subsite and stage: a population-based study // Eur J Cancer. ‒ 2000. ‒ T. 36, № 1. ‒ C. 95-9.
46. Khattak M. A., Martin H., Davidson A., Phillips M. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials // Clin Colorectal Cancer. ‒ 2015. ‒ T. 14, № 2. ‒ C. 81-90.
47. Pietrantonio F., Petrelli F., Coinu A., Di Bartolomeo M., Borgonovo K., Maggi C., Cabiddu M., Iacovelli R., Bossi I., Lonati V., Ghilardi M., de Braud F., Barni S. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis // Eur J Cancer. ‒ 2015. ‒ T. 51, № 5. ‒ C. 587-94.
48. Prasad V., Kaestner V., Mailankody S. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers // JAMA Oncol. ‒ 2018. ‒ T. 4, № 2. ‒ C. 157-158.
49. Therkildsen C., Bergmann T. K., Henrichsen-Schnack T., Ladelund S., Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis // Acta Oncol. ‒ 2014. ‒ T. 53, № 7. ‒ C. 852-64.
50. Wang X. Y., Zheng Z. X., Sun Y., Bai Y. H., Shi Y. F., Zhou L. X., Yao Y. F., Wu A. W., Cao D. F. Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas // World J Gastrointest Oncol. ‒ 2019. ‒ T. 11, № 4. ‒ C. 335-347.
51. Meric-Bernstam F., Hurwitz H., Raghav K. P. S., McWilliams R. R., Fakih M., VanderWalde A., Swanton C., Kurzrock R., Burris H., Sweeney C., Bose R., Spigel D. R., Beattie M. S., Blotner S., Stone A., Schulze K., Cuchelkar V., Hainsworth J. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study // Lancet Oncol. ‒ 2019. ‒ T. 20, № 4. ‒ C. 518-530.
52. Sartore-Bianchi A., Trusolino L., Martino C., Bencardino K., Lonardi S., Bergamo F., Zagonel V., Leone F., Depetris I., Martinelli E., Troiani T., Ciardiello F., Racca P., Bertotti A., Siravegna G., Torri V., Amatu A., Ghezzi S., Marrapese G., Palmeri L., Valtorta E., Cassingena A., Lauricella C., Vanzulli A., Regge D., Veronese S., Comoglio P. M., Bardelli A., Marsoni S., Siena S. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial // Lancet Oncol. ‒ 2016. ‒ T. 17, № 6. ‒ C. 738-746.
53. Li Q., Liu Y., Zhang H. M., Huang Y. P., Wang T. Y., Li D. S., Sun H. Z. Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis // Gastroenterol Res Pract. ‒ 2014. ‒ T. 2014. ‒ C. 827989.
54. Vikas P., Messersmith H., Compton C., Sholl L., Broaddus R. R., Davis A., Estevez-Diz M., Garje R., Konstantinopoulos P. A., Leiser A., Mills A. M., Norquist B., Overman M. J., Sohal D., Turkington R. C., Johnson T. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline // J Clin Oncol. ‒ 2023. ‒ T. 41, № 10. ‒ C. 1943-1948.
55. Jasperson K. W., Tuohy T. M., Neklason D. W., Burt R. W. Hereditary and familial colon cancer // Gastroenterology. ‒ 2010. ‒ T. 138, № 6. ‒ C. 2044-58.
56. Pabón M. MA; Babiker, HM A Review Of Hereditary Colorectal Cancers // StatPearls; StatPearls Publishing LLC.: Treasure Island, FL, USA. ‒ 2019.
57. Lugli A., Kirsch R., Ajioka Y., Bosman F., Cathomas G., Dawson H., El Zimaity H., Flejou J. F., Hansen T. P., Hartmann A., Kakar S., Langner C., Nagtegaal I., Puppa G., Riddell R., Ristimaki A., Sheahan K., Smyrk T., Sugihara K., Terris B., Ueno H., Vieth M., Zlobec I., Quirke P. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016 // Mod Pathol. ‒ 2017. ‒ T. 30, № 9. ‒ C. 1299-1311.
58. Loughrey M. B., Webster F., Arends M. J., Brown I., Burgart L. J., Cunningham C., Flejou J. F., Kakar S., Kirsch R., Kojima M., Lugli A., Rosty C., Sheahan K., West N. P., Wilson R. H., Nagtegaal I. D. Dataset for Pathology Reporting of Colorectal Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR) // Ann Surg. ‒ 2022. ‒ T. 275, № 3. ‒ C. e549-e561.
59. Burgart L. J., Chopp W. V., Jain D. Protocol for the examination of resection specimens from patients with primary carcinoma of the colon and rectum // CAP Cancer and CAP Pathology Electronic Reporting Committees. ‒ 2021. ‒ C. 1-28.
60. Johncilla M., Yantiss R. K. Histology of Colorectal Carcinoma: Proven and Purported Prognostic Factors // Surg Pathol Clin. ‒ 2020. ‒ T. 13, № 3. ‒ C. 503-520.
61. Trakarnsanga A., Gonen M., Shia J., Nash G. M., Temple L. K., Guillem J. G., Paty P. B., Goodman K. A., Wu A., Gollub M., Segal N., Saltz L., Garcia-Aguilar J., Weiser M. R. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment // J Natl Cancer Inst. ‒ 2014. ‒ T. 106, № 10.
62. Rosty C., Webster F., Nagtegaal I. D., Brown I., Cooper H. S., Dekker E., Driman D. K., Gonzalez R. S., Hewett D. G., Loughrey M. B. Pathology reporting of colorectal local excision specimens: recommendations from the international collaboration on cancer reporting (ICCR) // Gastroenterology. ‒ 2021. ‒ T. 161, № 2. ‒ C. 382-387.
63. Ventana MMR IHC Panel. Interpretation Guide for Staining of Colorectal Tissue. Ventana Medical Systems, Inc. (2017), p. 1-51. //.
64. Bartley A. N., Mills A. M., Konnick E., Overman M., Ventura C. B., Souter L., Colasacco C., Stadler Z. K., Kerr S., Howitt B. E., Hampel H., Adams S. F., Johnson W., Magi-Galluzzi C., Sepulveda A. R., Broaddus R. R. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer // Arch Pathol Lab Med. ‒ 2022. ‒ T. 146, № 10. ‒ C. 1194-1210.
65. Valtorta E., Martino C., Sartore-Bianchi A., Penaullt-Llorca F., Viale G., Risio M., Rugge M., Grigioni W., Bencardino K., Lonardi S., Zagonel V., Leone F., Noe J., Ciardiello F., Pinto C., Labianca R., Mosconi S., Graiff C., Aprile G., Frau B., Garufi C., Loupakis F., Racca P., Tonini G., Lauricella C., Veronese S., Truini M., Siena S., Marsoni S., Gambacorta M. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study // Mod Pathol. ‒ 2015. ‒ T. 28, № 11. ‒ C. 1481-91.
66. Bartley A. N., Washington M. K., Ventura C. B., Ismaila N., Colasacco C., Benson A. B., 3rd, Carrato A., Gulley M. L., Jain D., Kakar S., Mackay H. J., Streutker C., Tang L., Troxell M., Ajani J. A. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology // Arch Pathol Lab Med. ‒ 2016. ‒ T. 140, № 12. ‒ C. 1345-1363.
67. Тест VENTANA pan-TRK (EPR17341). ООО «Рош Диагностика Рус» (2020), p. 1-4. www.med.roche.ru //.
68. Демидова И.А., Савелов Н.А., Гриневич В.Н. Руководство VENTANA по интерпретации иммуногистохимического окрашивания ALK при немелкоклеточном раке лёгкого (НМРЛ). Руководство по оценке ALK-статуса с использованием кроличьих моноклональных антител Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody. Ventana Medical Systems, Inc.(2018), p. 1-52. www.med.roche.ru //.
69. Первичное кроличье моноклональное антитело VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibodya. ООО «Рош Диагностика Рус» (2021), p. 1-4. www.med.roche.ru //.
70. Guerra G. R., Kong C. H., Warrier S. K., Lynch A. C., Heriot A. G., Ngan S. Y. Primary squamous cell carcinoma of the rectum: An update and implications for treatment // World J Gastrointest Surg. ‒ 2016. ‒ T. 8, № 3. ‒ C. 252-65.
71. Vyas N., Ahmad S., Bhuiyan K., Catalano C., Alkhawam H., Sogomonian R., Nguyen J., Walfish A., Aron J. Primary squamous cell carcinoma of the rectum: a case report and literature review // J Community Hosp Intern Med Perspect. ‒ 2016. ‒ T. 6, № 3. ‒ C. 31708.
72. Sturgeon J. D., Crane C. H., Krishnan S., Minsky B. D., Skibber J. M., Rodriguez-Bigas M. A., Chang G. J., You Y. N., Eng C., Das P. Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum // Am J Clin Oncol. ‒ 2017. ‒ T. 40, № 2. ‒ C. 163-166.
73. Клинические рекомендации. Хронический болевой синдром (ХБС) у взрослых пациентов, нуждающихся в паллиативной медицинской помощи. МЗ РФ. 2018. //.
74. Babaei M., Jansen L., Balavarca Y., Sjovall A., Bos A., van de Velde T., Moreau M., Liberale G., Goncalves A. F., Bento M. J., Ulrich C. M., Schrotz-King P., Lemmens V., Glimelius B., Brenner H. Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes // Clin Colorectal Cancer. ‒ 2018. ‒ T. 17, № 1. ‒ C. e129-e142.
75. Abraha I., Aristei C., Palumbo I., Lupattelli M., Trastulli S., Cirocchi R., De Florio R., Valentini V. Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma // Cochrane Database Syst Rev. ‒ 2018. ‒ T. 10, № 10. ‒ C. CD002102.
76. De Caluwe L., Van Nieuwenhove Y., Ceelen W. P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer // Cochrane Database Syst Rev. ‒ 2013. ‒ T. 2013, № 2. ‒ C. CD006041.
77. Ngan S. Y., Burmeister B., Fisher R. J., Solomon M., Goldstein D., Joseph D., Ackland S. P., Schache D., McClure B., McLachlan S. A., McKendrick J., Leong T., Hartopeanu C., Zalcberg J., Mackay J. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04 // J Clin Oncol. ‒ 2012. ‒ T. 30, № 31. ‒ C. 3827-33.
78. Du D., Su Z., Wang D., Liu W., Wei Z. Optimal Interval to Surgery After Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Systematic Review and Meta-analysis // Clin Colorectal Cancer. ‒ 2018. ‒ T. 17, № 1. ‒ C. 13-24.
79. Petrelli F., Sgroi G., Sarti E., Barni S. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies // Ann Surg. ‒ 2016. ‒ T. 263, № 3. ‒ C. 458-64.
80. Pettersson D., Cedermark B., Holm T., Radu C., Pahlman L., Glimelius B., Martling A. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer // Br J Surg. ‒ 2010. ‒ T. 97, № 4. ‒ C. 580-7.
81. Nilsson P. J., van Etten B., Hospers G. A., Pahlman L., van de Velde C. J., Beets-Tan R. G., Blomqvist L., Beukema J. C., Kapiteijn E., Marijnen C. A., Nagtegaal I. D., Wiggers T., Glimelius B. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial // BMC Cancer. ‒ 2013. ‒ T. 13. ‒ C. 279.
82. Jin J., Tang Y., Hu C., Jiang L. M., Jiang J., Li N., Liu W. Y., Chen S. L., Li S., Lu N. N., Cai Y., Li Y. H., Zhu Y., Cheng G. H., Zhang H. Y., Wang X., Zhu S. Y., Wang J., Li G. F., Yang J. L., Zhang K., Chi Y., Yang L., Zhou H. T., Zhou A. P., Zou S. M., Fang H., Wang S. L., Zhang H. Z., Wang X. S., Wei L. C., Wang W. L., Liu S. X., Gao Y. H., Li Y. X. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR) // J Clin Oncol. ‒ 2022. ‒ T. 40, № 15. ‒ C. 1681-1692.
83. Petrelli F., Trevisan F., Cabiddu M., Sgroi G., Bruschieri L., Rausa E., Ghidini M., Turati L. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes // Ann Surg. ‒ 2020. ‒ T. 271, № 3. ‒ C. 440-448.
84. Sychev S, Ponomarenko A, Chernyshov S, Alekseev M, Mamedli Z, Kuzmichev D, Polynovskiy A, Rybakov E. Total neoadjuvant therapy in rectal cancer: a network meta-analysis of randomized trials. Annals of Coloproctology. 2023 Aug;39(4):289 //.
85. Liao C. K., Kuo Y. T., Lin Y. C., Chern Y. J., Hsu Y. J., Yu Y. L., Chiang J. M., Hsieh P. S., Yeh C. Y., You J. F. Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy before Surgery for Treating Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis // Curr Oncol. ‒ 2022. ‒ T. 29, № 5. ‒ C. 3708-3727.
86. Verheij F. S., Omer D. M. R., Williams H., Buckley J. T., Lin S. T., Qin L.-X., Thompson H. M., Yuval J. B., Gollub M. J., Wu A. J.-C. Sustained organ preservation in patients with rectal cancer treated with total neoadjuvant therapy: Long-term results of the OPRA trial // Book Sustained organ preservation in patients with rectal cancer treated with total neoadjuvant therapy: Long-term results of the OPRA trial / EditorAmerican Society of Clinical Oncology, 2023.
87. Romesser P. B., Park B. K., Nemirovsky D., Alvarez J., Omer D. M., Sarkar R., Verheij F. S., Yamner M., Reyngold M., Hajj C. Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy // Book Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy / EditorAmerican Society of Clinical Oncology, 2023.
88. van der Valk M. J. M., Hilling D. E., Bastiaannet E., Meershoek-Klein Kranenbarg E., Beets G. L., Figueiredo N. L., Habr-Gama A., Perez R. O., Renehan A. G., van de Velde C. J. H., Consortium I. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study // Lancet. ‒ 2018. ‒ T. 391, № 10139. ‒ C. 2537-2545.
89. Dossa F., Chesney T. R., Acuna S. A., Baxter N. N. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis // Lancet Gastroenterol Hepatol. ‒ 2017. ‒ T. 2, № 7. ‒ C. 501-513.
90. Latkauskas T., Pauzas H., Gineikiene I., Janciauskiene R., Juozaityte E., Saladzinskas Z., Tamelis A., Pavalkis D. Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery // Colorectal Dis. ‒ 2012. ‒ T. 14, № 3. ‒ C. 294-8.
91. Cercek A., Roxburgh C. S. D., Strombom P., Smith J. J., Temple L. K. F., Nash G. M., Guillem J. G., Paty P. B., Yaeger R., Stadler Z. K., Seier K., Gonen M., Segal N. H., Reidy D. L., Varghese A., Shia J., Vakiani E., Wu A. J., Crane C. H., Gollub M. J., Garcia-Aguilar J., Saltz L. B., Weiser M. R. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer // JAMA Oncol. ‒ 2018. ‒ T. 4, № 6. ‒ C. e180071.
92. McCarthy K., Pearson K., Fulton R., Hewitt J. Pre‐operative chemoradiation for non‐metastatic locally advanced rectal cancer // Cochrane database of systematic reviews. ‒ 2012. № 12.
93. Lumish M. A., Cohen J. L., Stadler Z. K., Weiss J. A., Lamendola-Essel M. F., Yaeger R., Segal N. H., El Dika I. H., Saltz L. B., Shcherba M. PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer // Book PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer / EditorAmerican Society of Clinical Oncology, 2022.
94. Mei W. J., Wang X. Z., Li Y. F., Sun Y. M., Yang C. K., Lin J. Z., Wu Z. G., Zhang R., Wang W., Li Y., Zhuang Y. Z., Lei J., Wan X. B., Ren Y. K., Cheng Y., Li W. L., Wang Z. Q., Xu D. B., Mo X. W., Ju H. X., Ye S. W., Zhao J. L., Zhang H., Gao Y. H., Zeng Z. F., Xiao W. W., Zhang X. P., Zhang X., Xie E., Feng Y. F., Tang J. H., Wu X. J., Chen G., Li L. R., Lu Z. H., Wan D. S., Bei J. X., Pan Z. Z., Ding P. R. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial // Ann Surg. ‒ 2023. ‒ T. 277, № 4. ‒ C. 557-564.
95. Basch E., Dueck A. C., Mitchell S. A., Mamon H., Weiser M., Saltz L., Gollub M., Rogak L., Ginos B., Mazza G. L., Colgrove B., Chang G., Minasian L., Denicoff A., Thanarajasingam G., Musher B., George T., Venook A., Farma J., O'Reilly E., Meyerhardt J. A., Shi Q., Schrag D. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048) // J Clin Oncol. ‒ 2023. ‒ T. 41, № 21. ‒ C. 3724-3734.
96. Taylor F. G., Quirke P., Heald R. J., Moran B., Blomqvist L., Swift I., Sebag-Montefiore D. J., Tekkis P., Brown G., group M. s. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study // Ann Surg. ‒ 2011. ‒ T. 253, № 4. ‒ C. 711-9.
97. Kennedy E. D., Simunovic M., Jhaveri K., Kirsch R., Brierley J., Drolet S., Brown C., Vos P. M., Xiong W., MacLean T., Kanthan S., Stotland P., Raphael S., Chow G., O'Brien C. A., Cho C., Streutker C., Wong R., Schmocker S., Liberman S., Reinhold C., Kopek N., Marcus V., Bouchard A., Lavoie C., Morin S., Perigny M., Wright A., Neumann K., Clarke S., Patil N. G., Arnason T., Williams L., McLeod R., Brown G., Mathieson A., Pooni A., Baxter N. N. Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With "Good Prognosis" Rectal Cancer Eligible for Primary Surgery: The Phase 2 Nonrandomized QuickSilver Clinical Trial // JAMA Oncol. ‒ 2019. ‒ T. 5, № 7. ‒ C. 961-966.
98. Morton D., Seymour M., Magill L., Handley K., Glasbey J., Glimelius B., Palmer A., Seligmann J., Laurberg S., Murakami K., West N., Quirke P., Gray R., Group F. O. C. Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial // J Clin Oncol. ‒ 2023. ‒ T. 41, № 8. ‒ C. 1541-1552.
99. Marinello F. G., Frasson M., Baguena G., Flor-Lorente B., Cervantes A., Rosello S., Espi A., Garcia-Granero E. Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary // Dis Colon Rectum. ‒ 2015. ‒ T. 58, № 6. ‒ C. 556-65.
100. Rosenberg R., Maak M., Schuster T., Becker K., Friess H., Gertler R. Does a rectal cancer of the upper third behave more like a colon or a rectal cancer? // Dis Colon Rectum. ‒ 2010. ‒ T. 53, № 5. ‒ C. 761-70.
101. Sager O., Dincoglan F., Demiral S., Uysal B., Gamsiz H., Dirican B., Beyzadeoglu M. A Concise Review of Pelvic Radiation Therapy (RT) for Rectal Cancer with Synchronous Liver Metastases // Int J Surg Oncol. ‒ 2019. ‒ T. 2019. ‒ C. 5239042.
102. Kim M. J., Kim S. J., Park S. C., Kim D. Y., Park J. W., Ryoo S. B., Jeong S. Y., Park K. J., Oh H. K., Kim D. W., Kang S. B., Joo J. N., Oh J. H., Group S. E. C. Adjuvant radiotherapy for the treatment of stage IV rectal cancer after curative resection: A propensity score-matched analysis and meta-analysis // Medicine (Baltimore). ‒ 2016. ‒ T. 95, № 47. ‒ C. e4925.
103. Liu Q., Shan Z., Luo D., Cai S., Li Q., Li X. Palliative beam radiotherapy offered real-world survival benefit to metastatic rectal cancer: A large US population-based and propensity score-matched study // J Cancer. ‒ 2019. ‒ T. 10, № 5. ‒ C. 1216-1225.
104. Chen J. H., Ye Q., Huang F. Determining the survival benefit of postoperative radiotherapy in patients with pT1-3N1M0 rectal cancer undergoing total mesorectal excision: a retrospective analysis // BMC Gastroenterol. ‒ 2023. ‒ T. 23, № 1. ‒ C. 83.
105. Yu D., Wang Y., Song Y., Gao P., Sun J., Chen X., Hu Y., Wang Z. The efficacy of postoperative radiotherapy for locally advanced rectal cancer without neoadjuvant therapy // Translational Cancer Research. ‒ 2018. ‒ T. 7, № 4.
106. van der Pas M. H., Haglind E., Cuesta M. A., Furst A., Lacy A. M., Hop W. C., Bonjer H. J., Group C. O. c. L. o. O. R. I. S. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial // Lancet Oncol. ‒ 2013. ‒ T. 14, № 3. ‒ C. 210-8.
107. Jeong S. Y., Park J. W., Nam B. H., Kim S., Kang S. B., Lim S. B., Choi H. S., Kim D. W., Chang H. J., Kim D. Y., Jung K. H., Kim T. Y., Kang G. H., Chie E. K., Kim S. Y., Sohn D. K., Kim D. H., Kim J. S., Lee H. S., Kim J. H., Oh J. H. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial // Lancet Oncol. ‒ 2014. ‒ T. 15, № 7. ‒ C. 767-74.
108. Green B. L., Marshall H. C., Collinson F., Quirke P., Guillou P., Jayne D. G., Brown J. M. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer // Br J Surg. ‒ 2013. ‒ T. 100, № 1. ‒ C. 75-82.
109. Schwenk W., Haase O., Neudecker J., Muller J. M. Short term benefits for laparoscopic colorectal resection // Cochrane Database Syst Rev. ‒ 2005. ‒ T. 2005, № 3. ‒ C. CD003145.
110. Ribas Y., Hotouras A., Wexner S. D., D'Hoore A. Shared decision-making and informed consent process in rectal cancer treatment: weighing up oncological and functional outcomes // Colorectal Dis. ‒ 2016. ‒ T. 18, № 1. ‒ C. 9-12.
111. Breukink S., Pierie J., Wiggers T. Laparoscopic versus open total mesorectal excision for rectal cancer // Cochrane Database Syst Rev. ‒ 2006.10.1002/14651858.CD005200.pub2 № 4. ‒ C. CD005200.
112. Chude G. G., Rayate N. V., Patris V., Koshariya M., Jagad R., Kawamoto J., Lygidakis N. J. Defunctioning loop ileostomy with low anterior resection for distal rectal cancer: should we make an ileostomy as a routine procedure? A prospective randomized study // Hepatogastroenterology. ‒ 2008. ‒ T. 55, № 86-87. ‒ C. 1562-7.
113. Гордеев С., Иванов В., Расулов А., Барсуков Ю., Ткачев С., Сураева Ю., Черных М., Кузьмичев Д., Козак Е., Малихов А. Химиолучевая терапия осложненного местнораспространенного и рецидивного рака прямой кишки. Медицинская радиология и радиационная безопасность 2016;61(6):57‒63. //.
114. Wang L., Chen X., Liao C., Wu Q., Luo H., Yi F., Wei Y., Zhang W. Early versus late closure of temporary ileostomy after rectal cancer surgery: a meta-analysis // Surg Today. ‒ 2021. ‒ T. 51, № 4. ‒ C. 463-471.
115. Elsner A. T., Brosi P., Walensi M., Uhlmann M., Egger B., Glaser C., Maurer C. A. Closure of Temporary Ileostomy 2 Versus 12 Weeks After Rectal Resection for Cancer: A Word of Caution From a Prospective, Randomized Controlled Multicenter Trial // Dis Colon Rectum. ‒ 2021. ‒ T. 64, № 11. ‒ C. 1398-1406.
116. Park J., Angenete E., Bock D., Correa-Marinez A., Danielsen A. K., Gehrman J., Haglind E., Jansen J. E., Skullman S., Wedin A., Rosenberg J. Cost analysis in a randomized trial of early closure of a temporary ileostomy after rectal resection for cancer (EASY trial) // Surg Endosc. ‒ 2020. ‒ T. 34, № 1. ‒ C. 69-76.
117. Danielsen A. K., Park J., Jansen J. E., Bock D., Skullman S., Wedin A., Marinez A. C., Haglind E., Angenete E., Rosenberg J. Early Closure of a Temporary Ileostomy in Patients With Rectal Cancer: A Multicenter Randomized Controlled Trial // Ann Surg. ‒ 2017. ‒ T. 265, № 2. ‒ C. 284-290.
118. Kye B. H., Kim H. J., Kim J. G., Cho H. M. Is it safe the reversal of a diverting stoma during adjuvant chemotherapy in elderly rectal cancer patients? // Int J Surg. ‒ 2014. ‒ T. 12, № 12. ‒ C. 1337-41.
119. Hajibandeh S., Hajibandeh S., Sarma D. R., East J., Zaman S., Mankotia R., Thompson C. V., Torrance A. W., Peravali R. Meta-analysis of temporary loop ileostomy closure during or after adjuvant chemotherapy following rectal cancer resection: the dilemma remains // Int J Colorectal Dis. ‒ 2019. ‒ T. 34, № 7. ‒ C. 1151-1159.
120. Nascimbeni R., Nivatvongs S., Larson D. R., Burgart L. J. Long-term survival after local excision for T1 carcinoma of the rectum // Dis Colon Rectum. ‒ 2004. ‒ T. 47, № 11. ‒ C. 1773-9.
121. Sgourakis G., Lanitis S., Gockel I., Kontovounisios C., Karaliotas C., Tsiftsi K., Tsiamis A., Karaliotas C. C. Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-analysis and meta-regression analysis of outcomes // Am Surg. ‒ 2011. ‒ T. 77, № 6. ‒ C. 761-72.
122. Doornebosch P. G., Tollenaar R. A., De Graaf E. J. Is the increasing role of Transanal Endoscopic Microsurgery in curation for T1 rectal cancer justified? A systematic review // Acta Oncol. ‒ 2009. ‒ T. 48, № 3. ‒ C. 343-53.
123. Чернышов С.В., Нагудов М.А., Хомяков Е.А., Козырева С.Б., Майновская О.А., Рыбаков Е.Г. Результаты тотальной мезоректумэктомии и трансанальной эндомикрохирургии при аденокарциномах прямой кишки с инвазией в подслизистый слой. Хирургия. Журнал им. Н.И. Пирогова. 2022;(4):34 41. //.
124. Maynovskaia O, Rybakov E, Chernyshov S, Khomyakov E, Achkasov S. Are the width, length, depth, and area of submucosal invasion predictive of lymph node metastasis in pT1 colorectal cancer? Ann Coloproctol. 2023;39(6):484-492. //.
125. Zwager L. W., Bastiaansen B. A. J., Montazeri N. S. M., Hompes R., Barresi V., Ichimasa K., Kawachi H., Machado I., Masaki T., Sheng W., Tanaka S., Togashi K., Yasue C., Fockens P., Moons L. M. G., Dekker E. Deep Submucosal Invasion Is Not an Independent Risk Factor for Lymph Node Metastasis in T1 Colorectal Cancer: A Meta-Analysis // Gastroenterology. ‒ 2022. ‒ T. 163, № 1. ‒ C. 174-189.
126. Cho S. H., Choi G. S., Kim G. C., Seo A. N., Kim H. J., Kim W. H., Shin K. M., Lee S. M., Ryeom H., Kim S. H. Long-term outcomes of surgery alone versus surgery following preoperative chemoradiotherapy for early T3 rectal cancer: A propensity score analysis // Medicine (Baltimore). ‒ 2017. ‒ T. 96, № 12. ‒ C. e6362.
127. Tessier L., McKechnie T., Lee Y., Park L. J., Gangam N., Eskicioglu C. Laparoscopic ovarian transposition prior to pelvic radiation in young women with anorectal malignancies: a systematic review and meta-analysis of prevalence // Colorectal Dis. ‒ 2023. ‒ T. 25, № 7. ‒ C. 1336-1348.
128. Allard M. A., Adam R., Giuliante F., Lapointe R., Hubert C., Ijzermans J. N. M., Mirza D. F., Elias D., Laurent C., Gruenberger T., Poston G., Letoublon C., Isoniemi H., Lucidi V., Popescu I., Figueras J. Long-term outcomes of patients with 10 or more colorectal liver metastases // Br J Cancer. ‒ 2017. ‒ T. 117, № 5. ‒ C. 604-611.
129. Adam R., Wicherts D. A., de Haas R. J., Ciacio O., Levi F., Paule B., Ducreux M., Azoulay D., Bismuth H., Castaing D. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? // J Clin Oncol. ‒ 2009. ‒ T. 27, № 11. ‒ C. 1829-35.
130. Brandi G., De Lorenzo S., Nannini M., Curti S., Ottone M., Dall'Olio F. G., Barbera M. A., Pantaleo M. A., Biasco G. Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis // World J Gastroenterol. ‒ 2016. ‒ T. 22, № 2. ‒ C. 519-33.
131. Overman M. J., McDermott R., Leach J. L., Lonardi S., Lenz H. J., Morse M. A., Desai J., Hill A., Axelson M., Moss R. A., Goldberg M. V., Cao Z. A., Ledeine J. M., Maglinte G. A., Kopetz S., Andre T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study // Lancet Oncol. ‒ 2017. ‒ T. 18, № 9. ‒ C. 1182-1191.
132. Andre T., Shiu K. K., Kim T. W., Jensen B. V., Jensen L. H., Punt C., Smith D., Garcia-Carbonero R., Benavides M., Gibbs P., de la Fouchardiere C., Rivera F., Elez E., Bendell J., Le D. T., Yoshino T., Van Cutsem E., Yang P., Farooqui M. Z. H., Marinello P., Diaz L. A., Jr., Investigators K.-. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer // N Engl J Med. ‒ 2020. ‒ T. 383, № 23. ‒ C. 2207-2218.
133. Lenz H.-J., Lonardi S., Zagonel V., Van Cutsem E., Limon M. L., Wong K. Y. M., Hendlisz A., Aglietta M., Garcia-Alfonso P., Neyns B. Nivolumab (NIVO)+ low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update // Book Nivolumab (NIVO)+ low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update / EditorAmerican Society of Clinical Oncology, 2019.
134. Modest D. P., Martens U. M., Riera-Knorrenschild J., Greeve J., Florschutz A., Wessendorf S., Ettrich T., Kanzler S., Norenberg D., Ricke J., Seidensticker M., Held S., Buechner-Steudel P., Atzpodien J., Heinemann V., Seufferlein T., Tannapfel A., Reinacher-Schick A. C., Geissler M. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) // J Clin Oncol. ‒ 2019. ‒ T. 37, № 35. ‒ C. 3401-3411.
135. Федянин М., Трякин А., Тюляндин С. Потенциальные предикторы эффективности анти-EGFR-терапии при метастатическом раке толстой кишки. Онкологическая колопроктология 2013;2. //.
136. Wang J., Luo L., Wang D., Guo B., Li J., Yang Z., Tang D. Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta-analysis // J Cell Biochem. ‒ 2018. ‒ T. 119, № 2. ‒ C. 1521-1537.
137. Chen M., Wang Z., Liu Z., Deng T., Wang X., Chang Z., Zhang Q., Yang W., Liu N., Ji Z., Zhang X., Wang X., Peng Z., Li Y., Cao Y., Jin X., Lu H., Qu H., Tang Y., Xu C., Fang W., Zhang H., Yan D., Wang L., Li J., Zhang J., Wang Q., Xue L., Yin F., Han G., Cheng Z., Liu Q., Jin Y., Zhang Y., Li L., Cao B., Yao Y., Chen Z., Zou J., Ying J., Wei Q., Tian T., Zhao W., Li L., Zhang T., Song F., Ba Y. E., Li N., Gao H., Ji Y., Bao L., Zhao X., Cai J., Yuan Z., Shen L., Li J. PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study // JCO Precis Oncol. ‒ 2023. ‒ T. 7. ‒ C. e2200463.
138. Mutlu A. U., Aytac E., Gulmez M., Erdamar S., Ozer L. Case Report: Chemoimmunotherapy in microsatellite-instability-high advanced goblet cell carcinoma of the colon // Front Immunol. ‒ 2023. ‒ T. 14. ‒ C. 1160586.
139. Ree A. H., Saltyte Benth J., Hamre H. M., Kersten C., Hofsli E., Guren M. G., Sorbye H., Johansen C., Negard A., Bjornetro T., Nilsen H. L., Berg J. P., Flatmark K., Meltzer S. First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial // Br J Cancer. ‒ 2024. ‒ T. 130, № 12. ‒ C. 1921-1928.
140. Cetinkaya E., Dogrul A. B., Tirnaksiz M. B. Role of self expandable stents in management of colorectal cancers // World J Gastrointest Oncol. ‒ 2016. ‒ T. 8, № 1. ‒ C. 113-20.
141. Nielsen M. B., Laurberg S., Holm T. Current management of locally recurrent rectal cancer // Colorectal Dis. ‒ 2011. ‒ T. 13, № 7. ‒ C. 732-42.
142. Rahbari N. N., Ulrich A. B., Bruckner T., Munter M., Nickles A., Contin P., Loffler T., Reissfelder C., Koch M., Buchler M. W., Weitz J. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure? // Ann Surg. ‒ 2011. ‒ T. 253, № 3. ‒ C. 522-33.
143. Lee J. H., Kim D. Y., Kim S. Y., Park J. W., Choi H. S., Oh J. H., Chang H. J., Kim T. H., Park S. W. Clinical outcomes of chemoradiotherapy for locally recurrent rectal cancer // Radiat Oncol. ‒ 2011. ‒ T. 6. ‒ C. 51.
144. Tanis P. J., Doeksen A., van Lanschot J. J. Intentionally curative treatment of locally recurrent rectal cancer: a systematic review // Can J Surg. ‒ 2013. ‒ T. 56, № 2. ‒ C. 135-44.
145. Bird T. G., Ngan S. Y., Chu J., Kroon R., Lynch A. C., Heriot A. G. Outcomes and prognostic factors of multimodality treatment for locally recurrent rectal cancer with curative intent // Int J Colorectal Dis. ‒ 2018. ‒ T. 33, № 4. ‒ C. 393-401.
146. Watanabe J., Shoji H., Hamaguchi T., Miyamoto T., Hirano H., Iwasa S., Honma Y., Takashima A., Kato K., Ito Y., Itami J., Kanemitsu Y., Boku N. Chemoradiotherapy for Local Recurrence of Rectal Cancer: A Single Center Study of 18 Patients // In Vivo. ‒ 2019. ‒ T. 33, № 4. ‒ C. 1363-1368.
147. Yu S. K., Bhangu A., Tait D. M., Tekkis P., Wotherspoon A., Brown G. Chemoradiotherapy response in recurrent rectal cancer // Cancer Med. ‒ 2014. ‒ T. 3, № 1. ‒ C. 111-7.
148. Guren M. G., Undseth C., Rekstad B. L., Braendengen M., Dueland S., Spindler K. L., Glynne-Jones R., Tveit K. M. Reirradiation of locally recurrent rectal cancer: a systematic review // Radiother Oncol. ‒ 2014. ‒ T. 113, № 2. ‒ C. 151-7.
149. Petrelli F., Coinu A., Lonati V., Barni S. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer // Int J Colorectal Dis. ‒ 2015. ‒ T. 30, № 4. ‒ C. 447-57.
150. Andre T., Colin P., Louvet C., Gamelin E., Bouche O., Achille E., Colbert N., Boaziz C., Piedbois P., Tubiana-Mathieu N., Boutan-Laroze A., Flesch M., Billiau V., Buyse M., Gramont A., Groupe d'Etude et de Recherche Clinique en Oncologie R. Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies // Semin Oncol. ‒ 2001. ‒ T. 28, № 1 Suppl 1. ‒ C. 35-40.
151. Breugom A. J., van Gijn W., Muller E. W., Berglund A., van den Broek C. B. M., Fokstuen T., Gelderblom H., Kapiteijn E., Leer J. W. H., Marijnen C. A. M., Martijn H., Meershoek-Klein Kranenbarg E., Nagtegaal I. D., Pahlman L., Punt C. J. A., Putter H., Roodvoets A. G. H., Rutten H. J. T., Steup W. H., Glimelius B., van de Velde C. J. H. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial // Ann Oncol. ‒ 2015. ‒ T. 26, № 4. ‒ C. 696-701.
152. Guo Y., Xiong B. H., Zhang T., Cheng Y., Ma L. XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis // Cancer Invest. ‒ 2016. ‒ T. 34, № 2. ‒ C. 94-104.
153. Kato T., Nagata N., Fujii M., Takemoto H., Kondo K., Okuyama Y., Tominaga H., Sakamoto J., Mishima H. Multi-center phase II study of FLOX for advanced colorectal cancer patients in Japan: SWIFT 3 study // Anticancer Res. ‒ 2011. ‒ T. 31, № 12. ‒ C. 4657-64.
154. Andre T., Quinaux E., Louvet C., Colin P., Gamelin E., Bouche O., Achille E., Piedbois P., Tubiana-Mathieu N., Boutan-Laroze A., Flesch M., Lledo G., Raoul Y., Debrix I., Buyse M., de Gramont A. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1 // J Clin Oncol. ‒ 2007. ‒ T. 25, № 24. ‒ C. 3732-8.
155. Mizushima T., Ikeda M., Kato T., Ikeda A., Nishimura J., Hata T., Matsuda C., Satoh T., Mori M., Doki Y. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study // BMC Cancer. ‒ 2019. ‒ T. 19, № 1. ‒ C. 929.
156. Федянин М., Трякин А., Тюляндин С. Адъювантная химиотерапия после химиолучевого лечения рака прямой кишки. Онкологическая колопроктология 2014; 2. //.
157. Andre T., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., Bonetti A., Clingan P., Bridgewater J., Rivera F., de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial // J Clin Oncol. ‒ 2009. ‒ T. 27, № 19. ‒ C. 3109-16.
158. Kuebler J. P., Wieand H. S., O'Connell M. J., Smith R. E., Colangelo L. H., Yothers G., Petrelli N. J., Findlay M. P., Seay T. E., Atkins J. N., Zapas J. L., Goodwin J. W., Fehrenbacher L., Ramanathan R. K., Conley B. A., Flynn P. J., Soori G., Colman L. K., Levine E. A., Lanier K. S., Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07 // J Clin Oncol. ‒ 2007. ‒ T. 25, № 16. ‒ C. 2198-204.
159. McCleary N. J., Meyerhardt J. A., Green E., Yothers G., de Gramont A., Van Cutsem E., O'Connell M., Twelves C. J., Saltz L. B., Haller D. G., Sargent D. J. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database // J Clin Oncol. ‒ 2013. ‒ T. 31, № 20. ‒ C. 2600-6.
160. Cheeseman S. L., Joel S. P., Chester J. D., Wilson G., Dent J. T., Richards F. J., Seymour M. T. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer // Br J Cancer. ‒ 2002. ‒ T. 87, № 4. ‒ C. 393-9.
161. Hirsch B. R., Zafar S. Y. Capecitabine in the management of colorectal cancer // Cancer Manag Res. ‒ 2011. ‒ T. 3. ‒ C. 79-89.
162. Matsumoto S., Nishimura T., Kanai M., Mori Y., Nagayama S., Kawamura J., Nomura A., Miyamoto S., Kitano T., Ishiguro H., Yanagihara K., Teramukai S., Sakai Y., Chiba T., Fukushima M. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study // Chemotherapy. ‒ 2008. ‒ T. 54, № 5. ‒ C. 395-403.
163. Cassidy J., Tabernero J., Twelves C., Brunet R., Butts C., Conroy T., Debraud F., Figer A., Grossmann J., Sawada N., Schoffski P., Sobrero A., Van Cutsem E., Diaz-Rubio E. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer // J Clin Oncol. ‒ 2004. ‒ T. 22, № 11. ‒ C. 2084-91.
164. Demir L., Somali I., Oktay Tarhan M., Erten C., Ellidokuz H., Can A., Dirican A., Vedat Bayoglu I. The toxicity and efficacy of Nordic-FLOX regimen as adjuvant treatment of stage III colon cancer // J BUON. ‒ 2011. ‒ T. 16, № 4. ‒ C. 682-8.
165. Sorbye H., Glimelius B., Berglund A., Fokstuen T., Tveit K. M., Braendengen M., Ogreid D., Dahl O. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer // J Clin Oncol. ‒ 2004. ‒ T. 22, № 1. ‒ C. 31-8.
166. Трякин А. А., Бесова Н. С., Волков Н. М., Гладков О. А., Карасева В. В., Сакаева Д. Д. и соавт. Общие принципы проведения противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли, 2023 (том 13), #3s2, стр. 28–41. //.
167. Moritani K., Kanemitsu Y., Shida D., Shitara K., Mizusawa J., Katayama H., Hamaguchi T., Shimada Y., Colorectal Cancer Study Group of Japan Clinical Oncology G. A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study) // Jpn J Clin Oncol. ‒ 2020. ‒ T. 50, № 1. ‒ C. 89-93.
168. Kanemitsu Y., Shitara K., Mizusawa J., Hamaguchi T., Shida D., Komori K., Ikeda S., Ojima H., Ike H., Shiomi A., Watanabe J., Takii Y., Yamaguchi T., Katsumata K., Ito M., Okuda J., Hyakudomi R., Shimada Y., Katayama H., Fukuda H., Group J. C. C. S. Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial // J Clin Oncol. ‒ 2021. ‒ T. 39, № 10. ‒ C. 1098-1107.
169. Seymour M. T., Maughan T. S., Ledermann J. A., Topham C., James R., Gwyther S. J., Smith D. B., Shepherd S., Maraveyas A., Ferry D. R., Meade A. M., Thompson L., Griffiths G. O., Parmar M. K., Stephens R. J., Investigators F. T., National Cancer Research Institute Colorectal Clinical Studies G. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial // Lancet. ‒ 2007. ‒ T. 370, № 9582. ‒ C. 143-152.
170. Cunningham D., Sirohi B., Pluzanska A., Utracka-Hutka B., Zaluski J., Glynne-Jones R., Koralewski P., Bridgewater J., Mainwaring P., Wasan H., Wang J. Y., Szczylik C., Clingan P., Chan R. T., Tabah-Fisch I., Cassidy J. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer // Ann Oncol. ‒ 2009. ‒ T. 20, № 2. ‒ C. 244-50.
171. Ackland S. P., Jones M., Tu D., Simes J., Yuen J., Sargeant A. M., Dhillon H., Goldberg R. M., Abdi E., Shepherd L., Moore M. J. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer // Br J Cancer. ‒ 2005. ‒ T. 93, № 11. ‒ C. 1236-43.
172. Matsuda A., Yamada T., Jamjittrong S., Shinji S., Ohta R., Sonoda H., Kamonvarapitak T., Sekiguchi K., Miyashita M., Suzuki H., Yoshida H. Comparison Between Biweekly and Weekly Cetuximab in Patients With Metastatic Colorectal Cancer: A Meta-analysis // Anticancer Res. ‒ 2020. ‒ T. 40, № 6. ‒ C. 3469-3476.
173. Munemoto Y., Nakamura M., Takahashi M., Kotaka M., Kuroda H., Kato T., Minagawa N., Noura S., Fukunaga M., Kuramochi H., Touyama T., Takahashi T., Miwa K., Satake H., Kurosawa S., Miura T., Mishima H., Sakamoto J., Oba K., Nagata N. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer // Eur J Cancer. ‒ 2019. ‒ T. 119. ‒ C. 158-167.
174. Modest D. P., Karthaus M., Fruehauf S., Graeven U., Muller L., Konig A. O., Fischer von Weikersthal L., Caca K., Kretzschmar A., Goekkurt E., Haas S., Kurreck A., Stahler A., Held S., Jarosch A., Horst D., Reinacher-Schick A., Kasper S., Heinemann V., Stintzing S., Trarbach T. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212) // J Clin Oncol. ‒ 2022. ‒ T. 40, № 1. ‒ C. 72-82.
175. Hurwitz H. I., Fehrenbacher L., Hainsworth J. D., Heim W., Berlin J., Holmgren E., Hambleton J., Novotny W. F., Kabbinavar F. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer // J Clin Oncol. ‒ 2005. ‒ T. 23, № 15. ‒ C. 3502-8.
176. Bendell J. C., Tournigand C., Swieboda-Sadlej A., Barone C., Wainberg Z. A., Kim J. G., Pericay C., Pastorelli D., Tarazi J., Rosbrook B., Bloom J., Ricart A. D., Kim S., Sobrero A. F. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study // Clin Colorectal Cancer. ‒ 2013. ‒ T. 12, № 4. ‒ C. 239-47.
177. Aparicio T., Bouche O., Taieb J., Maillard E., Kirscher S., Etienne P. L., Faroux R., Khemissa Akouz F., El Hajbi F., Locher C., Rinaldi Y., Lecomte T., Lavau-Denes S., Baconnier M., Oden-Gangloff A., Genet D., Paillaud E., Retornaz F., Francois E., Bedenne L., for P. I. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results // Ann Oncol. ‒ 2018. ‒ T. 29, № 1. ‒ C. 133-138.
178. Obermannova R., Van Cutsem E., Yoshino T., Bodoky G., Prausova J., Garcia-Carbonero R., Ciuleanu T., Garcia Alfonso P., Portnoy D., Cohn A., Yamazaki K., Clingan P., Lonardi S., Kim T. W., Yang L., Nasroulah F., Tabernero J. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression // Ann Oncol. ‒ 2016. ‒ T. 27, № 11. ‒ C. 2082-2090.
179. Verdaguer H., Tabernero J., Macarulla T. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy // Ther Adv Med Oncol. ‒ 2016. ‒ T. 8, № 3. ‒ C. 230-42.
180. Tabernero J., Yoshino T., Cohn A. L., Obermannova R., Bodoky G., Garcia-Carbonero R., Ciuleanu T. E., Portnoy D. C., Van Cutsem E., Grothey A., Prausova J., Garcia-Alfonso P., Yamazaki K., Clingan P. R., Lonardi S., Kim T. W., Simms L., Chang S. C., Nasroulah F., Investigators R. S. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study // Lancet Oncol. ‒ 2015. ‒ T. 16, № 5. ‒ C. 499-508.
181. Folprecht G., Pericay C., Saunders M. P., Thomas A., Lopez Lopez R., Roh J. K., Chistyakov V., Hohler T., Kim J. S., Hofheinz R. D., Ackland S. P., Swinson D., Kopp M., Udovitsa D., Hall M., Iveson T., Vogel A., Zalcberg J. R. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study // Ann Oncol. ‒ 2016. ‒ T. 27, № 7. ‒ C. 1273-9.
182. Van Cutsem E., Tabernero J., Lakomy R., Prenen H., Prausova J., Macarulla T., Ruff P., van Hazel G. A., Moiseyenko V., Ferry D., McKendrick J., Polikoff J., Tellier A., Castan R., Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen // J Clin Oncol. ‒ 2012. ‒ T. 30, № 28. ‒ C. 3499-506.
183. Cunningham D., Lang I., Marcuello E., Lorusso V., Ocvirk J., Shin D. B., Jonker D., Osborne S., Andre N., Waterkamp D., Saunders M. P., investigators A. s. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial // Lancet Oncol. ‒ 2013. ‒ T. 14, № 11. ‒ C. 1077-1085.
184. Alfonso P. G., Fernandez M. E., Alsar J. S., Paez D., Montes A. F., Suarez B. G., Salud A., Esteban A. Y., España M. G., Declara I. M. 560MO Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial // Annals of Oncology. ‒ 2023. ‒ T. 34. ‒ C. S416-S417.
185. Koukourakis G. V., Zacharias G., Tsalafoutas J., Theodoridis D., Kouloulias V. Capecitabine for locally advanced and metastatic colorectal cancer: A review // World J Gastrointest Oncol. ‒ 2010. ‒ T. 2, № 8. ‒ C. 311-21.
186. Petrioli R., Paolelli L., Marsili S., Civitelli S., Francini E., Cioppa T., Roviello F., Nettuno R., Intrivici C., Tanzini G., Lorenzi M., Francini G. FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer // Oncology. ‒ 2006. ‒ T. 70, № 5. ‒ C. 345-50.
187. Feliu J., Safont M. J., Salud A., Losa F., Garcia-Giron C., Bosch C., Escudero P., Lopez R., Madronal C., Bolanos M., Gil M., Llombart A., Castro-Carpeno J., Gonzalez-Baron M. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer // Br J Cancer. ‒ 2010. ‒ T. 102, № 10. ‒ C. 1468-73.
188. Динаева Э.А., и др. Значение эмпегфилграстима в интенсивных режимах терапии опухолей ЖКТ. Доклад на сессии отечественные исследования в онкологии, конференции «Опухоли ЖКТ» 15 апреля 2022 г. https://www.sciencedirect.com/science/article/pii/S2468294221001623. //.
189. Falandry C., Campone M., Cartron G., Guerin D., Freyer G. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines // Eur J Cancer. ‒ 2010. ‒ T. 46, № 13. ‒ C. 2389-98.
190. Aghedo B. O., Gupta V. Filgrastim //. ‒ 2020.
191. Baraniskin A., Buchberger B., Pox C., Graeven U., Holch J. W., Schmiegel W., Heinemann V. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis // Eur J Cancer. ‒ 2019. ‒ T. 106. ‒ C. 37-44.
192. Rosa B., de Jesus J. P., de Mello E. L., Cesar D., Correia M. M. Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis // Ecancermedicalscience. ‒ 2015. ‒ T. 9. ‒ C. 582.
193. Avallone A., Giuliani F., Nasti G., Montesarchio V., Santabarbara G., Leo S., De Stefano A., Rosati G., Lolli I., Tamburini E. Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study // Book Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study / EditorAmerican Society of Clinical Oncology, 2022.
194. Hijazi Y., Gondal U., Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery // Int J Surg. ‒ 2017. ‒ T. 39. ‒ C. 156-162.
195. Gillis C., Li C., Lee L., Awasthi R., Augustin B., Gamsa A., Liberman A. S., Stein B., Charlebois P., Feldman L. S., Carli F. Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer // Anesthesiology. ‒ 2014. ‒ T. 121, № 5. ‒ C. 937-47.
196. Shitara K., Ajani J. A., Moehler M., Garrido M., Gallardo C., Shen L., Yamaguchi K., Wyrwicz L., Skoczylas T., Bragagnoli A. C., Liu T., Tehfe M., Elimova E., Bruges R., Zander T., de Azevedo S., Kowalyszyn R., Pazo-Cid R., Schenker M., Cleary J. M., Yanez P., Feeney K., Karamouzis M. V., Poulart V., Lei M., Xiao H., Kondo K., Li M., Janjigian Y. Y. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer // Nature. ‒ 2022. ‒ T. 603, № 7903. ‒ C. 942-948.
197. Cohen R., Meurisse A., Pudlarz T., Bennouna J., Tournigand C., De La Fouchardiere C., Tougeron D., Borg C., Mazard T., Chibaudel B. One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study // Book One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study / EditorAmerican Society of Clinical Oncology, 2022.
198. Федянин М.Ю., Полянская Е.М., Трякин А.А., и др. Влияние стартовой дозы регорафениба на общую выживаемость пациентов с метастатическим раком толстой кишки: систематический обзор и метаанализ. Современная онкология 2019. Т. 21. №3. C. 10-15. doi: 10.26442/18151434.2019.3.190651 //.
199. Yoshino T., Di Bartolomeo M., Raghav K., Masuishi T., Loupakis F., Kawakami H., Yamaguchi K., Nishina T., Wainberg Z., Elez E., Rodriguez J., Fakih M., Ciardiello F., Saxena K., Kobayashi K., Bako E., Okuda Y., Meinhardt G., Grothey A., Siena S., investigators D.-C. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer // Nat Commun. ‒ 2023. ‒ T. 14, № 1. ‒ C. 3332.
200. Le D. T., Uram J. N., Wang H., Bartlett B. R., Kemberling H., Eyring A. D., Skora A. D., Luber B. S., Azad N. S., Laheru D., Biedrzycki B., Donehower R. C., Zaheer A., Fisher G. A., Crocenzi T. S., Lee J. J., Duffy S. M., Goldberg R. M., de la Chapelle A., Koshiji M., Bhaijee F., Huebner T., Hruban R. H., Wood L. D., Cuka N., Pardoll D. M., Papadopoulos N., Kinzler K. W., Zhou S., Cornish T. C., Taube J. M., Anders R. A., Eshleman J. R., Vogelstein B., Diaz L. A., Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency // N Engl J Med. ‒ 2015. ‒ T. 372, № 26. ‒ C. 2509-20.
201. Overman M. J., Lonardi S., Wong K. Y. M., Lenz H. J., Gelsomino F., Aglietta M., Morse M. A., Van Cutsem E., McDermott R., Hill A., Sawyer M. B., Hendlisz A., Neyns B., Svrcek M., Moss R. A., Ledeine J. M., Cao Z. A., Kamble S., Kopetz S., Andre T. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer // J Clin Oncol. ‒ 2018. ‒ T. 36, № 8. ‒ C. 773-779.
202. Le D. T., Kim T. W., Van Cutsem E., Geva R., Jager D., Hara H., Burge M., O'Neil B., Kavan P., Yoshino T., Guimbaud R., Taniguchi H., Elez E., Al-Batran S. E., Boland P. M., Crocenzi T., Atreya C. E., Cui Y., Dai T., Marinello P., Diaz L. A., Jr., Andre T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164 // J Clin Oncol. ‒ 2020. ‒ T. 38, № 1. ‒ C. 11-19.
203. Kostek O., Hacioglu M. B., Sakin A., Demir T., Sari M., Ozkul O., Araz M., Dogan A. F., Demircan N. C., Uzunoglu S., Cicin I., Erdogan B. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer? // Cancer Chemother Pharmacol. ‒ 2019. ‒ T. 83, № 1. ‒ C. 115-122.
204. Gundgaard M. G., Soerensen J. B., Ehrnrooth E. Third-line therapy for metastatic colorectal cancer // Cancer Chemother Pharmacol. ‒ 2008. ‒ T. 61, № 1. ‒ C. 1-13.
205. Walter T., Hawkins N. S., Pollock R. F., Colaone F., Shergill S., Ross P. J. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer // J Cancer Res Clin Oncol. ‒ 2020. ‒ T. 146, № 10. ‒ C. 2575-2587.
206. Cremolini C., Loupakis F., Antoniotti C., Lupi C., Sensi E., Lonardi S., Mezi S., Tomasello G., Ronzoni M., Zaniboni A., Tonini G., Carlomagno C., Allegrini G., Chiara S., D'Amico M., Granetto C., Cazzaniga M., Boni L., Fontanini G., Falcone A. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study // Lancet Oncol. ‒ 2015. ‒ T. 16, № 13. ‒ C. 1306-15.
207. Федянин М.Ю., Полянская Е.М., Эльснукаева Х.Х., Трякин А.А., Покатаев И.А., Буланов А.А., Тюляндин С.А. Метаанализ исследований по сравнению эффективности режимов FOLFOXIRI и FOLFOX или FOLFIRI с таргетной терапией при метастатическом раке толстой кишки с мутацией в гене BRAF. Медицинский Совет 2020;(20):125-132. https://doi.org/10.21518/2079-701X-2020-20-125-132 //.
208. Guo W., Zhang X., Wang Y., Zhang W., Liu X., Shen W., He Y., Zhu X., Chen Z., Wang H. Q. FOLFIRI versus irinotecan monodrug as second-line treatment in metastatic colorectal cancer patients: An open, multicenter, prospective, randomized controlled phase III clinical study // Book FOLFIRI versus irinotecan monodrug as second-line treatment in metastatic colorectal cancer patients: An open, multicenter, prospective, randomized controlled phase III clinical study / EditorAmerican Society of Clinical Oncology, 2020.
209. Wirapati P., Pomella V., Vandenbosch B., Kerr P., Maiello E., Grahame M. J., Curca R.-O. D., Karthaus M., Bridgewater J. A., Mihailov A. C. Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity // Annals of Oncology. ‒ 2017. ‒ T. 28. ‒ C. iii151-iii152.
210. Kopetz S., Guthrie K. A., Morris V. K., Lenz H. J., Magliocco A. M., Maru D., Yan Y., Lanman R., Manyam G., Hong D. S., Sorokin A., Atreya C. E., Diaz L. A., Allegra C., Raghav K. P., Wang S. E., Lieu C. H., McDonough S. L., Philip P. A., Hochster H. S. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406) // J Clin Oncol. ‒ 2021. ‒ T. 39, № 4. ‒ C. 285-294.
211. Bekaii-Saab T. S., Ou F. S., Ahn D. H., Boland P. M., Ciombor K. K., Heying E. N., Dockter T. J., Jacobs N. L., Pasche B. C., Cleary J. M., Meyers J. P., Desnoyers R. J., McCune J. S., Pedersen K., Barzi A., Chiorean E. G., Sloan J., Lacouture M. E., Lenz H. J., Grothey A. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study // Lancet Oncol. ‒ 2019. ‒ T. 20, № 8. ‒ C. 1070-1082.
212. Trullas A., Delgado J., Genazzani A., Mueller-Berghaus J., Migali C., Muller-Egert S., Zander H., Enzmann H., Pignatti F. The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer // ESMO Open. ‒ 2021. ‒ T. 6, № 3. ‒ C. 100145.
213. Freshwater T., Kondic A., Ahamadi M., Li C. H., de Greef R., de Alwis D., Stone J. A. Evaluation of dosing strategy for pembrolizumab for oncology indications // J Immunother Cancer. ‒ 2017. ‒ T. 5. ‒ C. 43.
214. Andre T., Elez E., Van Cutsem E., Jensen L. H., Bennouna J., Mendez G., Schenker M., De La Fouchardiere C., Limon M. L., Yoshino T. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study // Book Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study / EditorAmerican Society of Clinical Oncology, 2024.
215. Kanat O., Ertas H. Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy // World J Clin Oncol. ‒ 2019. ‒ T. 10, № 2. ‒ C. 52-61.
216. Corcoran R. B., Andre T., Atreya C. E., Schellens J. H. M., Yoshino T., Bendell J. C., Hollebecque A., McRee A. J., Siena S., Middleton G., Muro K., Gordon M. S., Tabernero J., Yaeger R., O'Dwyer P. J., Humblet Y., De Vos F., Jung A. S., Brase J. C., Jaeger S., Bettinger S., Mookerjee B., Rangwala F., Van Cutsem E. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer // Cancer Discov. ‒ 2018. ‒ T. 8, № 4. ‒ C. 428-443.
217. Wu Z., Huang M., Gong Y., Lin C., Guo W. BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells // Acta Biochim Biophys Sin (Shanghai). ‒ 2018. ‒ T. 50, № 4. ‒ C. 355-361.
218. M. Fedyanin1, H. Elsnukaeva1, I. Demidova , et al. 448P - Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice. Annals of Oncology (2021) 32 (suppl_5): S530-S582. doi: 10.1016/annonc/annonc698 //.
219. Yaeger R., Cercek A., O'Reilly E. M., Reidy D. L., Kemeny N., Wolinsky T., Capanu M., Gollub M. J., Rosen N., Berger M. F., Lacouture M. E., Vakiani E., Saltz L. B. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients // Clin Cancer Res. ‒ 2015. ‒ T. 21, № 6. ‒ C. 1313-20.
220. Hyman D. M., Puzanov I., Subbiah V., Faris J. E., Chau I., Blay J. Y., Wolf J., Raje N. S., Diamond E. L., Hollebecque A., Gervais R., Elez-Fernandez M. E., Italiano A., Hofheinz R. D., Hidalgo M., Chan E., Schuler M., Lasserre S. F., Makrutzki M., Sirzen F., Veronese M. L., Tabernero J., Baselga J. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations // N Engl J Med. ‒ 2015. ‒ T. 373, № 8. ‒ C. 726-36.
221. Corcoran R. B., Atreya C. E., Falchook G. S., Kwak E. L., Ryan D. P., Bendell J. C., Hamid O., Messersmith W. A., Daud A., Kurzrock R., Pierobon M., Sun P., Cunningham E., Little S., Orford K., Motwani M., Bai Y., Patel K., Venook A. P., Kopetz S. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer // J Clin Oncol. ‒ 2015. ‒ T. 33, № 34. ‒ C. 4023-31.
222. Klute K. A., Rothe M., Garrett-Mayer E., Mangat P. K., Nazemzadeh R., Yost K. J., Duvivier H. L., Ahn E. R., Cannon T. L., Alese O. B., Krauss J. C., Thota R., Calfa C. J., Denlinger C. S., O'Lone R., Halabi S., Grantham G. N., Schilsky R. L. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study // JCO Precis Oncol. ‒ 2022. ‒ T. 6. ‒ C. e2200191.
223. Chen Y., Li X., Yuxin M., Hu H., Wang L., Zhang Z., Chen P., Liu Y., Lu J., Lin T. Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer // Book Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer / EditorAmerican Society of Clinical Oncology, 2023.
224. Piringer G., Decker J., Trommet V., Kühr T., Heibl S., Dörfler K., Thaler J. Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: a case report and literature review // Frontiers in Oncology. ‒ 2023. ‒ T. 13. ‒ C. 1166545.
225. Messersmith W. A. NCCN Guidelines Updates: Management of Metastatic Colorectal Cancer // J Natl Compr Canc Netw. ‒ 2019. ‒ T. 17, № 5.5. ‒ C. 599-601.
226. Zaanan A., Dabout V., Garinet S., Giraud D., Perkins G., Taieb J., Gallois C. Encorafenib, binimetinib and cetuximab in BRAF V600E-mutated advanced pancreatic adenocarcinoma // ESMO Open. ‒ 2024. ‒ T. 9, № 11. ‒ C. 103975.
227. Van Cutsem E., Taieb J., Yaeger R., Yoshino T., Grothey A., Maiello E., Elez E., Dekervel J., Ross P., Ruiz-Casado A., Graham J., Kato T., Ruffinelli J. C., Andre T., Carriere Roussel E., Klauck I., Groc M., Vedovato J. C., Tabernero J. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer // J Clin Oncol. ‒ 2023. ‒ T. 41, № 14. ‒ C. 2628-2637.
228. Kopetz S., Grothey A., Yaeger R., Van Cutsem E., Desai J., Yoshino T., Wasan H., Ciardiello F., Loupakis F., Hong Y. S. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer // New England Journal of Medicine. ‒ 2019. ‒ T. 381, № 17. ‒ C. 1632-1643.
229. Capalbo C., Marchetti P., Coppa A., Calogero A., Anastasi E., Buffone A., Belardinilli F., Gulino M., Frati P., Catalano C., Cortesi E., Giannini G., Gulino A. Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report // Cancer Biol Ther. ‒ 2014. ‒ T. 15, № 7. ‒ C. 826-31.
230. Fox D. A., Bhamidipati D., Kopetz S., Hong D. S. Durable Remission After Targeted Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Case Report // J Immunother Precis Oncol. ‒ 2025. ‒ T. 8, № 1. ‒ C. 11-14.
231. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL. Rectal cancer, version 1.2025, NCCN clinical practice guidelines in oncology. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf //.
232. Tabernero J., Yoshino T., Kim T., Yaeger R., Desai J., Wasan H., Van Cutsem E., Ciardiello F., Maughan T., Eng C. LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E)+ cetuximab (C)+ chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC) // Annals of Oncology. ‒ 2022. ‒ T. 33. ‒ C. S1392-S1393.
233. Wang Z., Qin B. D., Ye C. Y., Wang M. M., Yuan L. Y., Dai W. P., Sun L., Liu K., Qin W. X., Jiao X. D., Li X. N., Zang Y. S. Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial // Eur J Cancer. ‒ 2022. ‒ T. 163. ‒ C. 152-162.
234. Bayraktar B., Ozemir I. A., Kefeli U., Demiral G., Sagiroglu J., Bayraktar O., Adali G., Ozcelik A., Tortum O. B. Colorectal stenting for palliation and as a bridge to surgery: A 5-year follow-up study // World J Gastroenterol. ‒ 2015. ‒ T. 21, № 31. ‒ C. 9373-9.
235. Cameron M. G., Kersten C., Vistad I., Fossa S., Guren M. G. Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review // Acta Oncol. ‒ 2014. ‒ T. 53, № 2. ‒ C. 164-73.
236. Costi R., Leonardi F., Zanoni D., Violi V., Roncoroni L. Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist // World J Gastroenterol. ‒ 2014. ‒ T. 20, № 24. ‒ C. 7602-21.
237. Navari R. M., Qin R., Ruddy K. J., Liu H., Powell S. F., Bajaj M., Dietrich L., Biggs D., Lafky J. M., Loprinzi C. L. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting // N Engl J Med. ‒ 2016. ‒ T. 375, № 2. ‒ C. 134-42.
238. Piechotta V., Adams A., Haque M., Scheckel B., Kreuzberger N., Monsef I., Jordan K., Kuhr K., Skoetz N. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis // Cochrane Database Syst Rev. ‒ 2021. ‒ T. 11, № 11. ‒ C. CD012775.
239. Владимирова Л.Ю., Гладков О.А., Королева И.А., Румянцев А.А., Семиглазова Т.Ю., Трякин А.А., Кутукова С.И., Овчинникова Е.Г., Новикова О.Ю., Корниецкая А.Л. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=nausea_vomiting //.
240. Chen C., Li R., Yang T., Ma L., Zhou S., Li M., Zhou Y., Cui Y. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials // Clin Ther. ‒ 2020. ‒ T. 42, № 8. ‒ C. 1494-1507 e1.
241. Багрова С.Г., Басин Е.М., Борзов К.А., Бычкова Н.М., Деньгина Н. В., Копп М.В., Крылов В.В., Кочетова Т.Ю., Семиглазова Т.Ю. Профилактика и лечение патологии костной ткани при злокачественных новообразованиях. Практические рекомендации RUSSCO, часть 2. //.
242. Krishan S., Panditaratne N., Verma R., Robertson R. Incremental value of CT venography combined with pulmonary CT angiography for the detection of thromboembolic disease: systematic review and meta-analysis // AJR Am J Roentgenol. ‒ 2011. ‒ T. 196, № 5. ‒ C. 1065-72.
243. Samaranayake C. B., Anderson J., McCabe C., Zahir S. F., J W. U., Keir G. Direct oral anticoagulants for cancer-associated venous thromboembolisms: a systematic review and network meta-analysis // Intern Med J. ‒ 2022. ‒ T. 52, № 2. ‒ C. 272-281.
244. Knoll W., Fergusson N., Ivankovic V., Wang T. F., Caiano L., Auer R., Carrier M. Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature // Thromb Res. ‒ 2021. ‒ T. 204. ‒ C. 114-122.
245. Сомонова О.В., Антух Э.А., Варданян А.В., Громова Е.Г., Долгушин Б.И., Елизарова А.Л., Сакаева Д.Д., Сельчук В.Ю., Трякин А.А., Черкасов В.А. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=thromboembolism //.
246. NCCN Guidelines. Prevention and Treatment of Cancer-Related Infections. v.1, 2021. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf. //.
247. Kosaka Y., Rai Y., Masuda N., Takano T., Saeki T., Nakamura S., Shimazaki R., Ito Y., Tokuda Y., Tamura K. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy // Support Care Cancer. ‒ 2015. ‒ T. 23, № 4. ‒ C. 1137-43.
248. Paul M., Yahav D., Fraser A., Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials // J Antimicrob Chemother. ‒ 2006. ‒ T. 57, № 2. ‒ C. 176-89.
249. Сакаева Д.Д., Борисов К.Е., Булавина И.С., Когония Л.М., Курмуков И.А., Орлова Р.В., Шабаева М.М. Практические рекомендации по диагностике и лечению фебрильной нейтропении. Практические рекомендации RUSSCO, часть 2. //.
250. Vincenzi B., Russo A., Terenzio A., Galvano A., Santini D., Vorini F., Antonelli-Incalzi R., Vespasiani-Gentilucci U., Tonini G. The use of SAMe in chemotherapy-induced liver injury // Crit Rev Oncol Hematol. ‒ 2018. ‒ T. 130. ‒ C. 70-77.
251. Remash D., Prince D. S., McKenzie C., Strasser S. I., Kao S., Liu K. Immune checkpoint inhibitor-related hepatotoxicity: A review // World J Gastroenterol. ‒ 2021. ‒ T. 27, № 32. ‒ C. 5376-5391.
252. Ткаченко П.Е., Ивашкин В.Т., Маевская М.В. Практические рекомендации по коррекции гепатотоксичности, индуцированной противоопухолевой терапией. Практические рекомендации RUSSCO, часть 2. //.
253. Mao Z., Shen K., Zhu L., Xu M., Yu F., Xue D., Li H., Xue C. Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials // Oncol Res Treat. ‒ 2019. ‒ T. 42, № 7-8. ‒ C. 405-413.
254. Albakri A. Systolic heart failure: A review of clinical status and meta-analysis of diagnosis and clinical management methods // Trends in Research. ‒ 2018. ‒ T. 1, № 4.
255. Tromp J., Ouwerkerk W., van Veldhuisen D. J., Hillege H. L., Richards A. M., van der Meer P., Anand I. S., Lam C. S. P., Voors A. A. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction // JACC Heart Fail. ‒ 2022. ‒ T. 10, № 2. ‒ C. 73-84.
256. Kalam K., Marwick T. H. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis // Eur J Cancer. ‒ 2013. ‒ T. 49, № 13. ‒ C. 2900-9.
257. Виценя М.В., Агеев Ф. Т., Орлова Р. В., Полтавская М.Г., Потиевская В.И. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 2 //.
258. Li J., Yan H. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials // Cancer Chemother Pharmacol. ‒ 2018. ‒ T. 82, № 4. ‒ C. 571-583.
259. Королева И.А., Болотина Л.В., Гладков О.А., Горбунова В.А., Когония Л.М., Круглова Л.С., Орлова Е.В., Орлова Р.В. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию. Практические рекомендации RUSSCO, часть 2. https://rosoncoweb.ru/standarts/?chapter=dermatological_reactions //.
260. Martin E. J., Bruggeman A. R., Nalawade V. V., Sarkar R. R., Qiao E. M., Rose B. S., Murphy J. D. Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer // J Natl Compr Canc Netw. ‒ 2020. ‒ T. 18, № 5. ‒ C. 569-574.
261. de van der Schueren M. A. E., Laviano A., Blanchard H., Jourdan M., Arends J., Baracos V. E. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials // Ann Oncol. ‒ 2018. ‒ T. 29, № 5. ‒ C. 1141-1153.
262. Сытов А.В., Зузов С.А., Кукош М.Ю., Лейдерман И.Н., Обухова О.А., Потапов А.Л., Хотеев А.Ж. Практические рекомендации по нутритивной поддержке онкологических больных. Практические рекомендации RUSSCO, часть 2. //.
263. Perazella M. A. Onco-nephrology: renal toxicities of chemotherapeutic agents // Clin J Am Soc Nephrol. ‒ 2012. ‒ T. 7, № 10. ‒ C. 1713-21.
264. Li H., Xu J., Bai Y., Zhang S., Cheng M., Jin J. Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis // Invest New Drugs. ‒ 2021. ‒ T. 39, № 3. ‒ C. 860-870.
265. Li S., He X., Ruan L., Ye T., Wen Y., Song Z., Hu S., Chen Y., Peng B., Li S. Protective Effect of Mannitol on Cisplatin-Induced Nephrotoxicity: A Systematic Review and Meta-Analysis // Front Oncol. ‒ 2021. ‒ T. 11. ‒ C. 804685.
266. Громова Е.Г., Бирюкова Л.С., Джумабаева Б.Т., Курмуков И.А. Практические рекомендации по коррекции нефротоксичности противоопухолевых препаратов. Практические рекомендации RUSSCO, часть 2. //.
267. NCCN guidelines. . Management of Immunotherapy-Related Toxicities. Version 4, 2021. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. //.
268. Johnson D. H., Zobniw C. M., Trinh V. A., Ma J., Bassett R. L., Jr., Abdel-Wahab N., Anderson J., Davis J. E., Joseph J., Uemura M., Noman A., Abu-Sbeih H., Yee C., Amaria R., Patel S., Tawbi H., Glitza I. C., Davies M. A., Wong M. K., Woodman S., Hwu W. J., Hwu P., Wang Y., Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis // J Immunother Cancer. ‒ 2018. ‒ T. 6, № 1. ‒ C. 103.
269. De Velasco G., Je Y., Bosse D., Awad M. M., Ott P. A., Moreira R. B., Schutz F., Bellmunt J., Sonpavde G. P., Hodi F. S., Choueiri T. K. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients // Cancer Immunol Res. ‒ 2017. ‒ T. 5, № 4. ‒ C. 312-318.
270. Zhang H., Li X., Huang X., Li J., Ma H., Zeng R. Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis // J Clin Pharm Ther. ‒ 2021. ‒ T. 46, № 4. ‒ C. 927-935.
271. Проценко С.А., Баллюзек М.Ф., Васильев Д.А., Жукова Н.В., Новик А.В., Носов Д.А., Петенко Н.Н., Семенова А.И., Харкевич Г.Ю., Юдин Д.И. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями. Практические рекомендации RUSSCO, часть 2. //.
272. Bossi P., Antonuzzo A., Cherny N. I., Rosengarten O., Pernot S., Trippa F., Schuler U., Snegovoy A., Jordan K., Ripamonti C. I., Committee E. G. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines // Ann Oncol. ‒ 2018. ‒ T. 29, № Suppl 4. ‒ C. iv126-iv142.
273. Peterson D. E., Bensadoun R. J., Roila F., Group E. G. W. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines // Ann Oncol. ‒ 2010. ‒ T. 21 Suppl 5. ‒ C. v261-5.
274. Семиглазова Т.Ю., Беляк Н.П., Владимирова Л.Ю., Корниецкая А.Л., Королева И.А., Нечаева М.Н., Раджабова З.А., Телетаева Г.М., Ткаченко Е.В. Практические рекомендации по лечению и профилактике мукозитов. Практические рекомендации RUSSCO, часть 2. //.
275. Ohashi Y., Uemura Y., Fujisaka Y., Sugiyama T., Ohmatsu H., Katsumata N., Okamoto R., Saijo N., Hotta T. Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials // Cancer Sci. ‒ 2013. ‒ T. 104, № 4. ‒ C. 481-5.
276. Gafter-Gvili A., Rozen-Zvi B., Vidal L., Leibovici L., Vansteenkiste J., Gafter U., Shpilberg O. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials // Acta Oncol. ‒ 2013. ‒ T. 52, № 1. ‒ C. 18-29.
277. Орлова Р.В., Гладков О.А., Кутукова С.И., Копп М.В., Королева И.А., Ларионова В.Б., Моисеенко В.М., Поддубная И.В., Птушкин В.В. Практические рекомендации по лечению анемии при злокачественных новообразованиях. Практические рекомендации RUSSCO, часть 2. //.
278. Zhang F., Shen A., Jin Y., Qiang W. The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews // BMC Complement Altern Med. ‒ 2018. ‒ T. 18, № 1. ‒ C. 236.
279. Сытов А.В., Зузов С.А., Кукош М.Ю., Лейдерман И.Н., Потапов А.Л., Хотеев А.Ж. Практические рекомендации по лечению синдрома анорексии-кахексии у онкологических больных. Практические рекомендации RUSSCO, часть 2. //.
280. Yeow M., Soh S., Yap R., Tay D., Low Y. F., Goh S. S. N., Yeo C. S., Lo Z. J. A systematic review and network meta-analysis of randomized controlled trials on choice of central venous access device for delivery of chemotherapy // J Vasc Surg Venous Lymphat Disord. ‒ 2022. ‒ T. 10, № 5. ‒ C. 1184-1191 e8.
281. Исянгулова А.З., Шин А.Р., Петкау В.В. Центральный венозный доступ. Практические рекомендации RUSSCO, часть 2. //.
282. Kreidieh F. Y., Moukadem H. A., El Saghir N. S. Overview, prevention and management of chemotherapy extravasation // World J Clin Oncol. ‒ 2016. ‒ T. 7, № 1. ‒ C. 87-97.
283. Буйденок Ю.В., Обухова О.А. Рекомендации по профилактике и лечению последствий экстравазации противоопухолевых препаратов. Практические рекомендации RUSSCO, часть 2. //.
284. Zielinska A., Wlodarczyk M., Makaro A., Salaga M., Fichna J. Management of pain in colorectal cancer patients // Crit Rev Oncol Hematol. ‒ 2021. ‒ T. 157. ‒ C. 103122.
285. Когония Л.М., Новиков Г.А., Орлова Р.В., Сидоров А.В., Королева И.А., Сакаева Д.Д. Практические рекомендации по лечению хронического болевого синдрома у взрослых онкологических больных. Практические рекомендации RUSSCO, часть 2. //.
286. Rosello S., Blasco I., Garcia Fabregat L., Cervantes A., Jordan K., Committee E. G. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines // Ann Oncol. ‒ 2017. ‒ T. 28, № suppl_4. ‒ C. iv100-iv118.
287. Орлова Р.В., Жабина А.С., Иванова А.К., Наталенко К.Е., Телетаева Г.М. Практические рекомендации по лечению инфузионных реакций при проведении противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 2. //.
288. Mustafayev K., Torres H. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies // Clin Microbiol Infect. ‒ 2022. ‒ T. 28, № 10. ‒ C. 1321-1327.
289. Феоктистова П.С., Винницкая Е.В., Нурмухаметова Е.А., Тихонов И.Н. Практические рекомендации по профилактике и лечению реактивации/обострения хронических вирусных гепатитов у пациентов, получающих противоопухолевую терапию. Практические рекомендации RUSSCO, часть 2. //.
290. Alberti P., Salvalaggio A., Argyriou A. A., Bruna J., Visentin A., Cavaletti G., Briani C. Neurological Complications of Conventional and Novel Anticancer Treatments // Cancers (Basel). ‒ 2022. ‒ T. 14, № 24.
291. Латипова Д.Х., Андреев В.В., Маслова Д.А., Новик А.В., Проценко С.А. Неврологические осложнения противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 2. //.
292. Deli T., Orosz M., Jakab A. Hormone Replacement Therapy in Cancer Survivors - Review of the Literature // Pathol Oncol Res. ‒ 2020. ‒ T. 26, № 1. ‒ C. 63-78.
293. Hoel D. G., Berwick M., de Gruijl F. R., Holick M. F. The risks and benefits of sun exposure 2016 // Dermatoendocrinol. ‒ 2016. ‒ T. 8, № 1. ‒ C. e1248325.
294. Maltser S., Cristian A., Silver J. K., Morris G. S., Stout N. L. A Focused Review of Safety Considerations in Cancer Rehabilitation // PM R. ‒ 2017. ‒ T. 9, № 9S2. ‒ C. S415-S428.
295. Derksen J. W. G., Beijer S., Koopman M., Verkooijen H. M., van de Poll-Franse L. V., May A. M. Monitoring potentially modifiable lifestyle factors in cancer survivors: A narrative review on currently available methodologies and innovations for large-scale surveillance // Eur J Cancer. ‒ 2018. ‒ T. 103. ‒ C. 327-340.
296. Arem H., Loftfield E. Cancer Epidemiology: A Survey of Modifiable Risk Factors for Prevention and Survivorship // Am J Lifestyle Med. ‒ 2018. ‒ T. 12, № 3. ‒ C. 200-210.
297. Vijayvergia N., Denlinger C. S. Lifestyle Factors in Cancer Survivorship: Where We Are and Where We Are Headed // J Pers Med. ‒ 2015. ‒ T. 5, № 3. ‒ C. 243-63.
298. Serfaty D. Update on the contraceptive contraindications // J Gynecol Obstet Hum Reprod. ‒ 2019. ‒ T. 48, № 5. ‒ C. 297-307.
299. Silver J. K., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes // Am J Phys Med Rehabil. ‒ 2013. ‒ T. 92, № 8. ‒ C. 715-27.
300. Greer N. L., Gunnar W. P., Dahm P., Lee A. E., MacDonald R., Shaukat A., Sultan S., Wilt T. J. Enhanced Recovery Protocols for Adults Undergoing Colorectal Surgery: A Systematic Review and Meta-analysis // Dis Colon Rectum. ‒ 2018. ‒ T. 61, № 9. ‒ C. 1108-1118.
301. Tsimopoulou I., Pasquali S., Howard R., Desai A., Gourevitch D., Tolosa I., Vohra R. Psychological Prehabilitation Before Cancer Surgery: A Systematic Review // Ann Surg Oncol. ‒ 2015. ‒ T. 22, № 13. ‒ C. 4117-23.
302. Li P., Fang F., Cai J. X., Tang D., Li Q. G., Wang D. R. Fast-track rehabilitation vs conventional care in laparoscopic colorectal resection for colorectal malignancy: a meta-analysis // World J Gastroenterol. ‒ 2013. ‒ T. 19, № 47. ‒ C. 9119-26.
303. Wren S. M., Martin M., Yoon J. K., Bech F. Postoperative pneumonia-prevention program for the inpatient surgical ward // J Am Coll Surg. ‒ 2010. ‒ T. 210, № 4. ‒ C. 491-5.
304. de Almeida E. P. M., de Almeida J. P., Landoni G., Galas F., Fukushima J. T., Fominskiy E., de Brito C. M. M., Cavichio L. B. L., de Almeida L. A. A., Ribeiro U., Jr., Osawa E. A., Diz M. P., Cecatto R. B., Battistella L. R., Hajjar L. A. Early mobilization programme improves functional capacity after major abdominal cancer surgery: a randomized controlled trial // Br J Anaesth. ‒ 2017. ‒ T. 119, № 5. ‒ C. 900-907.
305. Visser W. S., Te Riele W. W., Boerma D., van Ramshorst B., van Westreenen H. L. Pelvic floor rehabilitation to improve functional outcome after a low anterior resection: a systematic review // Ann Coloproctol. ‒ 2014. ‒ T. 30, № 3. ‒ C. 109-14.
306. Efthimiadis C., Basdanis G., Zatagias A., Tzeveleki I., Kosmidis C., Karamanlis E., Harlaftis N. Manometric and clinical evaluation of patients after low anterior resection for rectal cancer // Tech Coloproctol. ‒ 2004. ‒ T. 8 Suppl 1. ‒ C. s205-7.
307. Finnane A., Janda M., Hayes S. C. Review of the evidence of lymphedema treatment effect // Am J Phys Med Rehabil. ‒ 2015. ‒ T. 94, № 6. ‒ C. 483-98.
308. Cheville A. L., Kollasch J., Vandenberg J., Shen T., Grothey A., Gamble G., Basford J. R. A home-based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial // J Pain Symptom Manage. ‒ 2013. ‒ T. 45, № 5. ‒ C. 811-21.
309. Jeon J., Sato K., Niedzwiecki D., Ye X., Saltz L. B., Mayer R. J., Mowat R. B., Whittom R., Hantel A., Benson A., Wigler D. S., Atienza D., Messino M., Kindler H., Venook A., Fuchs C. S., Meyerhardt J. A. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance // Clin Colorectal Cancer. ‒ 2013. ‒ T. 12, № 4. ‒ C. 233-8.
310. Mosher C. E., Winger J. G., Given B. A., Helft P. R., O'Neil B. H. Mental health outcomes during colorectal cancer survivorship: a review of the literature // Psychooncology. ‒ 2016. ‒ T. 25, № 11. ‒ C. 1261-1270.
311. Mustian K. M., Alfano C. M., Heckler C., Kleckner A. S., Kleckner I. R., Leach C. R., Mohr D., Palesh O. G., Peppone L. J., Piper B. F., Scarpato J., Smith T., Sprod L. K., Miller S. M. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis // JAMA Oncol. ‒ 2017. ‒ T. 3, № 7. ‒ C. 961-968.
312. Kinkead B., Schettler P. J., Larson E. R., Carroll D., Sharenko M., Nettles J., Edwards S. A., Miller A. H., Torres M. A., Dunlop B. W., Rakofsky J. J., Rapaport M. H. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial // Cancer. ‒ 2018. ‒ T. 124, № 3. ‒ C. 546-554.
313. Bensadoun R. J., Nair R. G. Low-Level Laser Therapy in the Management of Mucositis and Dermatitis Induced by Cancer Therapy // Photomed Laser Surg. ‒ 2015. ‒ T. 33, № 10. ‒ C. 487-91.
314. Pita-Fernandez S., Alhayek-Ai M., Gonzalez-Martin C., Lopez-Calvino B., Seoane-Pillado T., Pertega-Diaz S. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis // Ann Oncol. ‒ 2015. ‒ T. 26, № 4. ‒ C. 644-656.
315. Jeffery M., Hickey B. E., Hider P. N. Follow-up strategies for patients treated for non-metastatic colorectal cancer // Cochrane Database Syst Rev. ‒ 2007.10.1002/14651858.CD002200.pub2 № 1. ‒ C. CD002200.
316. Lee S. L., Shin Y. R., Kim K. The added value of pelvic surveillance by MRI during postoperative follow-up of rectal cancer, with a focus on abbreviated MRI // Eur Radiol. ‒ 2020. ‒ T. 30, № 6. ‒ C. 3113-3124.
317. Hupkens B. J. P., Maas M., Martens M. H., Deserno W., Leijtens J. W. A., Nelemans P. J., Bakers F. C. H., Lambregts D. M. J., Beets G. L., Beets-Tan R. G. H. MRI surveillance for the detection of local recurrence in rectal cancer after transanal endoscopic microsurgery // Eur Radiol. ‒ 2017. ‒ T. 27, № 12. ‒ C. 4960-4969.
318. Jayaprakasam V. S., Alvarez J., Omer D. M., Gollub M. J., Smith J. J., Petkovska I. Watch-and-Wait Approach to Rectal Cancer: The Role of Imaging // Radiology. ‒ 2023. ‒ T. 307, № 1. ‒ C. e221529.
319. Omer D. M. R., Williams H., Lin S. T., Thompson H. M., Verheij F. S., Yuval J. B., Buckley J. T., Qin L.-X., Gollub M. J., Garcia-Aguilar J. Diagnostic performance of endoscopy and MRI in identifying true response among patients with rectal cancer treated with total neoadjuvant therapy and selective watch and wait or TME // Book Diagnostic performance of endoscopy and MRI in identifying true response among patients with rectal cancer treated with total neoadjuvant therapy and selective watch and wait or TME / EditorAmerican Society of Clinical Oncology, 2024.
320. Федянин М. Ю., Гладков О. А., Гордеев С. С. , Карачун А. М., Козлов Н. А., Мамедли З. З., Рыков И. В., Трякин А. А., Цуканов А. С., Черных М. В.. Рак ободочной кишки, ректосигмоидного соединения и прямой кишки. Практические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли 2024;14(3s2):263–322. https://rosoncoweb.ru/standarts/RUSSCO/2024/2024-1_1-14.pdf
Комментарии • 0
Чтобы оставить комментарий, пожалуйста, войдите на портал